This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Charles Daubeny: The legacy behind Oxford’s largest commercial life science development

Charles Daubeny: The legacy behind Oxford’s largest commercial life science development

20 Feb 2025

The Daubeny Project is The Oxford Science Park’s most ambitious development to date. Covering 450,000 sq ft over three buildings, the project will deliver world-class lab and office space for global science and technology companies. It is fitting that the project is named after Charles Daubeny, an eminent scientist and former fellow of Magdalen College, Oxford. This aligns with the Park’s ethos of fostering cutting-edge research and... Read more

Ellison Institute expands team of field-leading experts

Ellison Institute expands team of field-leading experts

19 Feb 2025

The Ellison Institute of Technology (EIT) has announced its founding team of world-leading scientists, engineers, policy experts and entrepreneurs. EIT's mission is to develop and deploy solutions to some of humanity's most enduring challenges. They are taking a new approach to scientific discovery, one that aligns research and industry more closely than current models. This means creating end-to-end commercial solutions that translate... Read more

Scancell’s Modi-1 Moditope® vaccine achieves early clinical validation in head and neck cancer.

Scancell’s Modi-1 Moditope® vaccine achieves early clinical validation in head and neck cancer.

10 Jan 2025

Modi-1 successfully achieved Simon stage 1 suggesting the combination of Modi-1 and checkpoint blockade is beneficial in HPV negative head and neck squamous cell carcinoma (SCCHN) This result supports the continuation of the study in this indication Moditope® patent granted by U.S. Patent and Trademark Office (USPTO) Scancell, a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, has achieved significant... Read more

Supporting companies to grow at The Oxford Science Park

Supporting companies to grow at The Oxford Science Park

16 Dec 2024

The Oxford Science Park is committed to supporting companies to grow at the Park. We listen to and work closely with current and prospective occupiers, digging into the detail of their requirements to deliver optimal space for office and lab working. Being able to grow at the Park spares companies the upheaval of a costly move and enables them to remain focused on core business activities. In addition, they benefit from the consistency of... Read more

Orbit Discovery and Evergreen Theragnostics expand research collaboration to advance targeted therapeutics development

Orbit Discovery and Evergreen Theragnostics expand research collaboration to advance targeted therapeutics development

10 Dec 2024

Orbit Discovery, a leading provider of peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical company at the forefront of precision medicine, have announced an extension to their research collaboration to find novel targeting peptides for radiopharmaceutical delivery. This collaboration expands upon a previous agreement signed between the companies in April 2023 whereby technology synergies have enabled the... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More